Disseminated Trichosporon infection is an uncommon but life-threatening fungal infection usually observed in immunocompromised hosts, especially in patients with hematological malignancies. 1 The outcome of disseminated trichosporonosis is usually poor, with a mortality rate of approximately 80%. 1 Although previous reports suggest that voriconazole (VRCZ) is efficacious, [1] [2] [3] clinical data on VRCZ therapy in pediatric patients are limited. 3, 4 Even if this infection is successfully treated, subsequent chemotherapy and/or hematopoietic SCT (HSCT) will be challenging. To our knowledge, there have been no reports on successful HSCT after disseminated trichosporonosis. Here, we report using VRCZ for both successful treatment of disseminated Trichosporon asahii infection and for subsequent cord blood transplantation in an infant with AML.
In March 2007, a 5-month-old girl with acute megakaryoblastic leukemia with t(1;22)(p13;q13) abnormality was started on induction chemotherapy and achieved a CR. She continued in CR after the first course of consolidation chemotherapy and received the second course consisting of cytarabine, mitoxantrone and etoposide in June 2007. At 12 days after the initiation of chemotherapy, her WBC count decreased to 0.05 Â 10 9 /L and she developed high fever. She was treated with panipenem/betamipron, minocycline, fosfluconazole and granulocyte CSF, and her fever subsided on the following day. At 4 days after the first episode of fever, she became febrile again and several erythematous papules appeared on her face and trunk (day 0). The antibiotics were changed to vancomycin and cefpirome, but high fever persisted. On day 2, her blood culture from day 0 was reported to be positive for a yeastlike fungus and micafungin was added to the chemotherapy. However, high fever persisted and she had mild respiratory distress on day 3. On day 4, the yeast-like fungus was identified as Trichosporon species and T. asahii DNA was subsequently detected by PCR. The minimum inhibitory concentrations of amphotericin B, 5-fluorocytosine, fluconazole, miconazole, itraconazole, micafungin and VRCZ against the T. asahii isolate were 2, 464, 4, 0.5, 1, 416 and 0.125 mg/mL, respectively. Serum cryptococcal Ag was found to be positive and antifungal agents were changed to i.v. VRCZ (6 mg/kg every 12 h on the first day and 4 mg/kg every 12 h on the following days). Although serum b-D-glucan was transiently positive on day 6 and day 8, the patient's blood cultures became negative after VRCZ therapy was begun and her temperature decreased to a low-grade fever with improvement in exanthema and respiratory distress on day 10. The VRCZ trough plasma concentration on day 11 was 1.07 mg/mL. On day 14, her WBC count and neutrophil count increased to greater than 1.0 Â 10 9 /L and 0.5 Â 10 9 /L, respectively, and on day 19 her low-grade fever subsided. At this time, the serum cryptococcal Ag was still positive and VRCZ was administered orally from day 32 (4 mg/kg every 12 h).
In August 2007, 6 weeks after the onset of Trichosporon infection, the patient underwent unrelated cord blood transplantation as scheduled because of the poor prognosis of infant AML with t(1;22)(p13;q13). On day À9, VRCZ administration was changed from oral to i.v. /L) occurred on day 26. Relapse of Trichosporon infection was not observed. Cryptococcal Ag was continuously positive after the onset of disseminated trichosporonosis but turned negative on day 28 after cord blood transplantation. The plasma-VRCZ trough level during prophylaxis use was 0.10-0.36 mg/mL (day 7, 0.13; day 13, 0.10; day 20, 0.28; day 26, 0.36 mg/mL). She remains in CR 30 months after cord blood transplantation.
To our knowledge, this is the first report on successful treatment of disseminated Trichosporon infection in an infant with hematological malignancy. We used VRCZ for the treatment of this infection because several reports indicated that VRCZ was efficacious in both adult and pediatric patients. [1] [2] [3] Although the pediatric use of VRCZ was recently approved in Europe and dosages of 7 mg/kg i.v. and 200 mg orally twice everyday were recommended for patients from 2 to o12 years of age, 5 the optimal dosing regimen for infants remains unknown. We started i.v. VRCZ therapy at a dose of 6 mg/kg every 12 h on the first day and modified it to 4 mg/kg every 12 h on the following days, according to the regimen approved in Japan for adult patients. After the initiation of VRCZ therapy, blood cultures turned negative, and the patient's symptoms gradually resolved. Recently, Neely et al. 6 reported that a VRCZ trough concentration 41000 ng/ mL (1 mg/mL) was associated with favorable outcomes in pediatric patients. In our patient, the trough plasma-VRCZ concentration on day 11 was 41 mg/mL (1.07 mg/mL) and an appropriate VRCZ concentration may have resulted in the favorable outcome. To establish the optimal dosing regimen of VRCZ for infants, more patients need to be evaluated. In addition, low-grade fever persisted despite VRCZ therapy and the fever subsided after recovery of the neutrophil count. This outcome indicates that, as previously suggested, neutrophil-count recovery is also important for eradication of Trichosporon infection. 7 To our knowledge, there have been no reports on successful HSCT following disseminated trichosporonosis. However, Asada et al. 2 reported successful treatment of breakthrough T. asahii fungemia and subsequent consolidation therapy with VRCZ in an adult patient with AML. Moreover, several reports have indicated that VRCZ administration for secondary prophylaxis against invasive fungal infections during HSCT is safe and effective; 8, 9 therefore, we used VRCZ to prevent the reactivation of trichosporonosis. VRCZ was administered i.v. at a dose of 4 mg/kg every 12 h and relapse of Trichosporon infection was not observed. Although serial measurements showed relatively low trough VRCZ concentrations (0.10-0.36 ı`g/ mL), the levels were higher than or almost equal to the minimum inhibitory concentration of VRCZ against the T. asahii isolate (0.125 mg/mL). Recently, Allinson et al. 10 reported on the efficacy of secondary antifungal prophylaxis using liposomal amphotericin B followed by oral VRCZ in pediatric HSCT recipients, and available data showed that mean trough-VRCZ concentrations were lower than 1 mg/mL in eight out of nine recipients. The optimal VRCZ concentration for preventing reactivation of invasive fungal infections may be lower than that required to eradicate these infections. More studies are needed to evaluate the efficacy of VRCZ and the optimal VRCZ concentration required for prophylaxis against disseminated Trichosporon infection.
